Top

BMC Medical Genetics

Published in:

Open Access 01-12-2013 | Research article

Lack of association between Fas rs180082polymorphism and risk of cervical cancer: an update by meta-analysis

Authors: Xu Chen, Wuning Mo, Qiliu Peng, Xiandu Su

Published in: BMC Medical Genetics | Issue 1/2013

Abstract

Background

The Fas rs180082 polymorphism has been reported to be associated with cervical cancer susceptibility, yet the results of these previous results have been inconsistent or controversial. The objective of this study was to explore whether the Fas rs180082 polymorphism confers susceptibility to cervical cancer.

Methods

The relevant studies were identified through a search of PubMed, Excerpta Medica Database (Embase), Elsevier Science Direct and Chinese Biomedical Literature Database (CBM) until July 2012. The association between the Fas rs180082 polymorphism and cervical cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).

Results

A total of 7 case–control studies were eventually identified. We found no association between Fas rs180082 polymorphism and cervical cancer susceptibility in overall population (G versus A: OR = 1.03, 95% CI = 0.99-1.07, P = 0.197; AG + GG versus AA: OR = 1.04, 95% CI = 0.98-1.09, P = 0.176; GG versus AA + AG: OR = 1.04, 95% CI = 0.84–1.31, P = 0.701). In subgroup analysis, similar results were found in Asian (G versus A: OR = 1.06, 95% CI = 0.97–1.15, P = 0.195; AG + GG versus AA: OR = 1.08, 95% CI = 0.98–1.19, P = 0.176; GG versus AA + AG: OR = 0.97, 95% CI = 0.51–1.84, P = 0.935) and African (G versus A: OR = 1.01, 95% CI = 0.97-1.15, P = 0.195; AG + GG versus AA: OR = 0.99, 95% CI = 0.91–1.07, P = 0.739; GG versus AA + AG: OR = 1.09, 95% CI = 0.94–1.25, P = 0.745).

Conclusion

This meta-analysis has shown that there is a lack of association of the Fas rs180082 polymorphisms with cervical cancer susceptibility. However, larger scale primary studies with the consideration of gene–gene and gene–environment interactions are still required to further evaluate the interaction of Fas rs180082 polymorphism with cervical cancer susceptibility.

Available only for authorised users

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed

Hausen HZ: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000, 92 (9): 690-698. 10.1093/jnci/92.9.690.CrossRefPubMed

Ueda M, Hung YC, Terai Y, Kanda K, Takehara M, Yamashita H, Yamaguchi H, Akise D, Yasuda M, Nishiyama K, et al: Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell. 2003, 16 (4): 241-251. 10.1111/j.1749-0774.2003.tb00158.x.CrossRefPubMed

Tsigris C, Chatzitheofylaktou A, Xiromeritis C, Nikiteas N, Yannopoulos A: Genetic association studies in digestive system malignancies. Anticancer Res. 2007, 27 (5): 3577-3587.PubMed

Dockrell DH: Apoptotic cell death in the pathogenesis of infectious diseases. J Infect. 2001, 42: 227-234. 10.1053/jinf.2001.0836.CrossRefPubMed

Zhang J, Xu X, Liu Y: Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol. 2004, 1: 186-192.PubMed

Nagata S: Apoptosis by death factor. Cell. 1997, 88 (3): 355-365. 10.1016/S0092-8674(00)81874-7.CrossRefPubMed

Butler LM, Hewett PJ, Butler WJ, Cowled PA: Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer. 1998, 77 (9): 1454-1459. 10.1038/bjc.1998.239.CrossRefPubMedPubMedCentral

Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, et al: Alterations of Fas(APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 1999, 59 (13): 3068-3072.PubMed

10.

Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y: Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology. 2000, 32 (4): 761-769. 10.1053/jhep.2000.18192.CrossRefPubMed

11.

Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, Hoffman M, Williamson AL, et al: Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009, 2: 238-10.1186/1756-0500-2-238.CrossRefPubMedPubMedCentral

12.

Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, Qiao J: Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009, 31 (1): 38-41.PubMed

13.

Kordi Tamandani DM, Sobti RC, Shekari M: Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 2008, 35 (3): 183-186.PubMed

14.

Kang S, Dong SM, Seo SS, Kim JW, Park SY: FAS -1377 A/G polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008, 180 (1): 1-5. 10.1016/j.cancergencyto.2007.09.002.CrossRefPubMed

15.

Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, Te Meerman GJ, van der Zee AG: Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005, 15: 282-290. 10.1111/j.1525-1438.2005.00433.x.CrossRefPubMed

16.

Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M: Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006, 16: 179-182. 10.1111/j.1525-1438.2006.00505.x.CrossRefPubMed

17.

Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, Zhang Z: FAS promoter polymorphisms and cancer risk:a meta-analysis based on 34 case–control studies. Carcinogenesis. 2009, 30 (3): 487-493. 10.1093/carcin/bgp016.CrossRefPubMed

18.

Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22 (4): 719-748.PubMed

19.

DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed

20.

Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21 (11): 1539-1558. 10.1002/sim.1186.CrossRefPubMed

21.

Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327 (7414): 557-560. 10.1136/bmj.327.7414.557.CrossRefPubMedPubMedCentral

22.

Munafo MR, Clark TG, Flint J: Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004, 129 (1): 39-44. 10.1016/j.psychres.2004.06.011.CrossRefPubMed

23.

Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N, Izuma S, Torii K, Tanaka I, Okamoto Y, et al: Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int. 1999, 189: 12-19.

24.

Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, Miao X, Tan W, Zhao D, Zhang X, et al: FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005, 202 (7): 967-974. 10.1084/jem.20050707.CrossRefPubMedPubMedCentral

25.

Engelmark MT, Renkema KY, Gyllensten UB: No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 2004, 112 (6): 1084-1085. 10.1002/ijc.20515.CrossRefPubMed

26.

Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, Gyllensten UB: Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer. 2007, 121 (11): 2451-2457. 10.1002/ijc.22989.CrossRefPubMed

27.

Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, Chu TY: Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol. 2005, 99 (1): 113-118. 10.1016/j.ygyno.2005.05.010.CrossRefPubMed

28.

Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY: Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003, 103 (2): 221-225. 10.1002/ijc.10800.CrossRefPubMed

29.

Guzman VB, Yambartsev A, Goncalves-Primo A, Silva ID, Carvalho CR, Ribalta JC, Goulart LR, Shulzhenko N, Gerbase-Delima M, Morgun A, et al: New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer. Hum Mol Genet. 2008, 17 (12): 1838-1844. 10.1093/hmg/ddn077.CrossRefPubMedPubMedCentral

30.

Ueda M, Hung YC, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M: Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol. 2005, 98 (1): 129-133. 10.1016/j.ygyno.2005.04.001.CrossRefPubMed

31.

Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, Girão MJ, Brenna SM, Syrjänen KJ: Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 2009, 30 (2): 142-144.PubMed

32.

Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ: Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med. 2004, 14 (3): 475-478.PubMed

33.

Lerma E, Romero M, Gallardo A, Pons C, Muñoz J, Fuentes J, Lloveras B, Catasus L, Prat J: Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch. 2008, 452 (1): 65-74. 10.1007/s00428-007-0535-z.CrossRefPubMed

34.

Zörnig M, Hueber A, Baum W, Evan G: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta. 2001, 1551 (2): F1-F37.PubMed

35.

Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, Kuwano M, Hara T: A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002, 29 (6): 1183-1188.PubMed

36.

Zhu Q, Wang T, Ren J, Hu K, Liu W, Wu G: FAS -670A/G polymorphism: a biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin Chim Acta. 2010, 411 (3–4): 179-183.CrossRefPubMed

37.

Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, Cho S, Park JY, Cha SI, Kim CH, et al: Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res. 2009, 15 (5): 1794-1800. 10.1158/1078-0432.CCR-08-1770.CrossRefPubMed

38.

Wang LE, Cheng L, Spitz MR, Wei Q: Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer. 2003, 42 (1): 1-8. 10.1016/S0169-5002(03)00276-9.CrossRefPubMed

39.

Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y: Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol. 2010, 25 (3): 555-561. 10.1111/j.1440-1746.2009.06116.x.CrossRefPubMed

40.

Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC, Van Dooren S, Galvão-Castro B, et al: Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008, 83 (1): 220-222.CrossRefPubMed

41.

Hu Y, Xu Y, Wang Y, Ouyang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Geng PL, et al: Prognostic role of apoptosis-related gene Fas-1377 and -670 polymorphisms in breast cancer. Zhonghua Zhong Liu Za Zhi. 2009, 31 (2): 104-107.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/14/71/prepub

Title: Lack of association between Fas rs180082polymorphism and risk of cervical cancer: an update by meta-analysis
Authors: Xu Chen
Wuning Mo
Qiliu Peng
Xiandu Su
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Medical Genetics / Issue 1/2013
Electronic ISSN: 1471-2350
DOI: https://doi.org/10.1186/1471-2350-14-71

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lack of association between Fas rs180082polymorphism and risk of cervical cancer: an update by meta-analysis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

SOD2gene Val16Ala polymorphism is associated with macroalbuminuria in Mexican Type 2 Diabetes patients: a comparative study and meta-analysis

Reduced genetic influence on childhood obesity in small for gestational age children

Mitochondrial DNA variant m.15218A > G in Finnish epilepsy patients who have maternal relatives with epilepsy, sensorineural hearing impairment or diabetes mellitus

Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1locus

Genetic variants associated with circulating MMP1 levels near matrix metalloproteinase genes on chromosome 11q21-22 in Taiwanese: interaction with obesity

A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome